Future studies may look at targeting the CD40 pathway as a potential therapeutic target ORLANDO, DECEMBER 7, 2025 - Researchers at The University of Texas MD Anderson Cancer Center have characterized ...
Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment. While effective at activating the immune system to kill cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback